Session XVIII: Metastatic colorectal cancer

A phase III trial of fluoropyrimidines (FP) plus bevacizumab (Bev) vs. Bev alone, or no treatment as maintenance strategy, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): AIO KRK 0207
SLIDES D. Arnold, et al, O-0027

Independent radiological evaluation of objective response early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306)
SLIDES V. Heinemann, et al., O-0030

CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
SLIDES A. Venook, et al., O-0019  Presentation of Study @ASCO-Press Conference

Which biological agent and for whom?
SLIDES Paulo M. Hoff, MD

Outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer randomized to FOLFIRI with or without cetuximab as first-line treatment
SLIDES F. Ciardiello, et al., O-0020

Outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer randomized to FOLFOX4 with or without cetuximab as first-line treatment
SLIDES S. Tejpar, et al., O-0021

Kommentar Prof. Dr. med. Volker Heinemann, München: